NCT02178722 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 20
- group Id
- BG004
- value
- 382
- group Id
- BG005
- value
- 444
- units
- Participants
- groups
- description
- Epacadostat 25 mg tablet orally twice daily (BID) starting on Cycle 1 Day 1 in combination with pembrolizumab 2 mg/kg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.
- id
- BG000
- title
- Phase 1: Epacadostat 25 mg BID
- description
- Epacadostat 50 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 2 mg/kg or 200mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.
- id
- BG001
- title
- Phase 1: Epacadostat 50 mg BID
- description
- Epacadostat 100 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 2 mg/kg or 200mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.
- id
- BG002
- title
- Phase 1: Epacadostat 100 mg BID
- description
- Epacadostat 300 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 200 mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.
- id
- BG003
- title
- Phase 1: Epacadostat 300 mg BID
- description
- Epacadostat 100 mg tablet orally BID in combination with pembrolizumab 200 mg intravenously every 3 weeks (Q3W).
- id
- BG004
- title
- Phase 2: Epacadostat 100 mg BID
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 18.01
- value
- 48.8
- group Id
- BG001
- spread
- 12.97
- value
- 60.8
- group Id
- BG002
- spread
- 13.67
- value
- 63.2
- group Id
- BG003
- spread
- 13.06
- value
- 59.2
- group Id
- BG004
- spread
- 11.60
- value
- 62.7
- group Id
- BG005
- spread
- 11.92
- value
- 62.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 181
- group Id
- BG005
- value
- 208
- title
- Female
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 201
- group Id
- BG005
- value
- 236
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 17
- group Id
- BG004
- value
- 337
- group Id
- BG005
- value
- 393
- title
- White/Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 19
- group Id
- BG005
- value
- 22
- title
- Black/African-American
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 15
- group Id
- BG005
- value
- 17
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- title
- Native Hawaiian/Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 9
- group Id
- BG005
- value
- 9
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 2
- title
- Missing
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 16
- group Id
- BG005
- value
- 18
- title
- Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 19
- group Id
- BG004
- value
- 353
- group Id
- BG005
- value
- 413
- title
- Not Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 10
- group Id
- BG005
- value
- 10
- title
- Unknown
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 2
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- title
- Missing
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The safety evaluable population included all participants enrolled in the study who received at least 1 dose of study drug (epacadostat or pembrolizumab).
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 20
- group Id
- BG004
- value
- 382
- group Id
- BG005
- value
- 444
- units
- Participants
- groups
- description
- Epacadostat 25 mg tablet orally twice daily (BID) starting on Cycle 1 Day 1 in combination with pembrolizumab 2 mg/kg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.
- id
- BG000
- title
- Phase 1: Epacadostat 25 mg BID
- description
- Epacadostat 50 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 2 mg/kg or 200mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.
- id
- BG001
- title
- Phase 1: Epacadostat 50 mg BID
- description
- Epacadostat 100 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 2 mg/kg or 200mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.
- id
- BG002
- title
- Phase 1: Epacadostat 100 mg BID
- description
- Epacadostat 300 mg tablet orally BID starting on Cycle 1 Day 1 in combination with pembrolizumab 200 mg administered intravenously every 3 weeks (Q3W) starting on Cycle 1 Day 1.
- id
- BG003
- title
- Phase 1: Epacadostat 300 mg BID
- description
- Epacadostat 100 mg tablet orally BID in combination with pembrolizumab 200 mg intravenously every 3 weeks (Q3W).
- id
- BG004
- title
- Phase 2: Epacadostat 100 mg BID
- description
- Total of all reporting groups
- id
- BG005
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 18.01
- value
- 48.8
- group Id
- BG001
- spread
- 12.97
- value
- 60.8
- group Id
- BG002
- spread
- 13.67
- value
- 63.2
- group Id
- BG003
- spread
- 13.06
- value
- 59.2
- group Id
- BG004
- spread
- 11.60
- value
- 62.7
- group Id
- BG005
- spread
- 11.92
- value
- 62.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 6
- group Id
- BG003
- value
- 9
- group Id
- BG004
- value
- 181
- group Id
- BG005
- value
- 208
- title
- Female
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 201
- group Id
- BG005
- value
- 236
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 17
- group Id
- BG004
- value
- 337
- group Id
- BG005
- value
- 393
- title
- White/Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 19
- group Id
- BG005
- value
- 22
- title
- Black/African-American
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 15
- group Id
- BG005
- value
- 17
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- title
- Native Hawaiian/Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 9
- group Id
- BG005
- value
- 9
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 2
- title
- Missing
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 16
- group Id
- BG005
- value
- 18
- title
- Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 20
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 19
- group Id
- BG004
- value
- 353
- group Id
- BG005
- value
- 413
- title
- Not Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 10
- group Id
- BG005
- value
- 10
- title
- Unknown
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 2
- title
- Other
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- title
- Missing
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The safety evaluable population included all participants enrolled in the study who received at least 1 dose of study drug (epacadostat or pembrolizumab).
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle